Efficacy and safety of tocilizumab in Chinese patients with systemic juvenile idiopathic arthritis: a multicentre phase IV trial
This is the first multicentre trial to report the efficacy and safety of TCZ in Chinese patients with sJIA at 52 weeks. No new safety concerns were found.
Authors
- Jiahui Xu (ORCID: https://orcid.org/0000-0003-2780-2217)
- Junmei Zhang
- Wenjie Zheng (ORCID: https://orcid.org/0000-0002-3165-8185)
- Yu Zhang (ORCID: https://orcid.org/0000-0001-8948-1434)
- Caifeng Li (ORCID: https://orcid.org/0009-0002-8217-6765)
- Haiguo Yu (ORCID: https://orcid.org/0000-0001-8255-9390)
- Sirui Yang (ORCID: https://orcid.org/0000-0001-7984-3569)
- Zhixuan Zhou (ORCID: https://orcid.org/0000-0003-0051-8208)
- Wei Zhou (ORCID: https://orcid.org/0000-0002-9610-3113)
- Xuemei Tang (ORCID: https://orcid.org/0000-0003-3905-0462)
- Yuxiu Kong
- Weiping Tan
- Meiping Lu
- Li Sun
Institutions
- Sun Yat-sen University (CN)
- Jilin University (CN)
- Wenzhou Medical University (CN)
- Shanghai Children's Medical Center (CN)
- Sun Yat-sen Memorial Hospital (CN)
- Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University (CN)
- Children's Hospital of Zhejiang University (CN)
- Roche (China) (CN)
- First Hospital of Jilin University (CN)
- Second Affiliated Hospital of Nanjing Medical University (CN)
- Beijing Children’s Hospital (CN)
- Children's Hospital of Fudan University (CN)
- Children's Hospital of Chongqing Medical University (CN)
- Children's Hospital of Capital Institute of Pediatrics (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- Clinical Rheumatology
- Published
- 2024-09-16
- DOI
- https://doi.org/10.1007/s10067-024-07126-9
- Citations
- 6
- Primary Topic
- Autoimmune and Inflammatory Disorders Research
- Type
- article
- Field-Weighted Citation Impact
- 2.73